Tufia Haddad, MD
Enriched profileAssociate professor of oncology, Mayo Clinic College of Medicine and Science · Mayo Clinic Rochester
Tufia Haddad is Associate professor of oncology, Mayo Clinic College of Medicine and Science at Mayo Clinic Rochester. OpenAlex indexes 279 publications with 6,047 citations (h-index 38); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 26 Oct 2026
Overview
Updated 28 Oct 2026
Tufia Haddad, MD, is Associate professor of oncology, Mayo Clinic College of Medicine and Science at Mayo Clinic Rochester. The public record shows 279 publications with 6,047 citations (h-index 38), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Telemedicine and Telehealth Implementation. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 5 companies, 2 NIH-funded awards (2017–2026).
- Most recent indexed publication: 2026 · BMJ open
- Top research focus: Breast Cancer Treatment Studies
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 92.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 28 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Workflow-Integrated Artificial Intelligence for RPM Enrollment
Sponsor: Mayo Clinic
Industry payments
Updated 28 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PUMA BIOTECHNOLOGY, INC.Program year20252 payments
- TAIHO ONCOLOGY, INC.Program year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50.2%Serotonin-3 Receptor Antagonist50.2%Palonosetron hcl54%Ondansetron hydrochloride46%Part B, office-administered≥15 patientsSensory organs
41.9%Corticosteroid41.9%Dexamethasone sodium phosphate100%Part B, office-administered≥21 patientsCancer & immunology
5.1%Aromatase Inhibitor5.1%Letrozole100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 28 Oct 2026
2 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Evaluation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: The SHIELD (Smart Health Integration for Early Life-saving Detection)
Mayo Clinic Rochester
FY2026$569,282UG3CA315308 - Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer
Mayo Clinic Rochester
FY2021$315,236R01CA214893 - Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer
Mayo Clinic Rochester
FY2020$324,060R01CA214893
Congress activity
Updated 28 Oct 2026
72 congress contributions (2010–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 2744: Automating clinical and pathological staging for breast cancer patients.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 28 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.
Current oncology reports
Review2024 - Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial.
Clinical cancer research
Clinical Trial2024 - Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast CancerArticle555 citations2016
- 03Adaptive Randomization of Neratinib in Early Breast CancerArticle455 citations2016
- 04Chemotherapy-induced thrombosisArticle359 citations2006
- 05
Network
Updated 28 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 28 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/tufia-haddad-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 28 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗
Editorial & leadership roles
journal and society appointments- Enterprise co-leader of Platform and Digital Innovation
Mayo Clinic Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗ - Chair of Practice Innovation and Platform
Mayo Clinic Comprehensive Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Medical Director of Care at Home
Center for Digital Health
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Edward Loftus, MD
Mayo Clinic Rochester
Martha Lacy, MD
Mayo Clinic Rochester
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope